 NEWTOWN, Pa., Feb. 16, 2021 GLOBE NEWSWIRE -- Onconova Therapeutics, Inc. NASDAQ: ONTX Onconova, a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the closing of its previously-announced underwritten public offering. A total of 28,750,000 shares of its common stock were sold, including 3,750,000 shares of common stock following the exercise by the underwriters of their over-allotment option, at a public offering price of 1.00 per share. The gross proceeds of the offering to the Company are 28.75 million, before deducting the underwriting discounts and commissions and other estimated offering expenses. 